fda semaglutide compounding enforcement october 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified Important Notice: Tirzepatide Compounding Update

This feature wasn't present in January 2026 coverage

This study found no association between GLP-1RAs and intestinal obstruction, while DPP-4 inhibitors were associated with an increased risk of obstruction

Another reason to adjust concentration is when you are switching between doses frequently

WEIGHT-LOSS DRUGS IMPACT ON CANCER RISK REVEALED IN NEW STUDY After starting the weight-loss medications, the participants weekly average alcohol intake decreased by almost two-thirds overall from approximately 11 units of alcohol to four units after four months of treatment with the GLP-1 agonists

Long-term safety data for this combination remains limited

Meta-Analysis: Chemoprevention of Hepatocellular Carcinoma with Statins, Aspirin and Metformin